| 张晓莹，白月洁，王子涵，吕颖玉，孙华茹，朱雪，张心月，邵雨萌.基于“肺为血脏”理论探讨气虚血瘀与肺纤维化[J].中医药信息,2025,42(10):7-11 |
| 基于“肺为血脏”理论探讨气虚血瘀与肺纤维化 |
| Exploring the Relationship between Qi Deficiency and Blood Stasis， and Pulmonary Fibrosis Based on the Theory of "Lung as the Blood Organ" |
| 投稿时间：2025-04-14 录用日期：2025-04-28 |
| DOI：10.19656/j.cnki.1002-2406.20251002 |
| 中文关键词: 肺为血脏 气虚血瘀 肺纤维化 病机 益气活血 |
| 英文关键词: Lung as the Blood Organ Qi deficiency and blood stasis Pulmonary fibrosis Pathogenesis Replenishing qi and activating blood circulation |
| 基金项目:国家自然科学基金资助项目(项目编号：82104799) |
|
| 摘要点击次数: 66 |
| 全文下载次数: 27 |
| 中文摘要: |
| 肺纤维化（PF）是呼吸系统疾病中的难治性疾病。“肺为血脏”理论认为肺具有生血、行血之功，肺脏参与并促进血液生成，通过“肺朝百脉”行血气以营养濡润形体官窍。肺为血脏，则易成血瘀。本文通过论述“肺为血脏”理论与现代医学肺脏造血功能的相关证据，阐明气虚血瘀与PF之间的内在关联，发现气虚血瘀贯穿于PF全程，故将PF分为三期：初期为肺气损伤，瘀血已生；慢性进展期为气血亏虚，痰瘀互结，络脉痹阻；终末期为肺、脾、肾三脏亏虚、气血不足，络虚而瘀。临证应以益气活血为核心治则，可抑制炎症反应、调节凝血系统、改善血管新生以及延缓纤维化进展，从而改善患者的肺功能并提高生存质量。 |
| 英文摘要: |
| Pulmonary fibrosis （PF） is a refractory disease in the respiratory system. The theory of "Lung as the Blood Organ" posits that the lung promotes blood generation， produce and circulate blood， and nourishes the body and orifices through its governance over the vessels. As the lung is regarded as the blood organ， it is prone to have blood stasis. This article elucidates the intrinsic connection of Qi deficiency and blood stasis with PF by discussing the theory of "Lung as the Blood Organ" and related evidence of the lung's hematopoietic function in modern medicine. It reveals that Qi deficiency and blood stasis persist throughout the progression of PF， which can be divided into three stages： the initial stage， characterized by lung Qi impairment with emerging blood stasis； the chronic progression stage， marked by Qi－blood deficiency， phlegm－stasis interaction， and collateral obstruction； and the terminal stage， involving deficiency of the lung， spleen and kidney， with Qi－blood insufficiency， and collateral deficiency with stasis. In clinical practice， the core treatment principle should focus on replenishing Qi and activating blood circulation， which can inhibit inflammatory responses， regulate the coagulation system， improve angiogenesis， and delay fibrosis progression， thereby enhancing patients' pulmonary function and quality of life. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
